Mortality rates and associated factors among people living with perinatally acquired HIV in Europe and Thailand

Developing and streamlining clinical trial services to support pediatric drug development across 21 countries in Europe: insights from the conect4children (c4c) network

The route to financial sustainability of a large Public Private Partnership—the example of the clinical trial network conect4children (c4c)

Bridging the knowledge gap: Insights from the THRIVE Training Gap Assessment

Growth trajectories before and after switching to dolutegravir in children living with HIV in the ODYSSEY trial

Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert

Growth outcomes in children living with HIV in Europe and Thailand before and after starting dolutegravir

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial

Causes of death among sub-Saharan African infants living with HIV and hospitalised with severe pneumonia, using minimally invasive autopsies in the EMPIRICAL trial

Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With Human Immunodeficiency Virus (HIV) on Dolutegravir in Europe and Thailand

Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?

Outcomes After Prenatal Exposure to Raltegravir-Containing Antiretroviral Therapy: A Multicohort European Study

Effect of Empirical Treatment with Valganciclovir on Mortality in Infants with Severe HIV -associated Pneumonia: a multicenter, open-label, randomized factorial clinical trial

Effectiveness and safety of dolutegravir (DTG) in infants and children aged under 12-years at start of DTG in Europe and Thailand

Empirical treatment against tuberculosis in infants with HIV-associated pneumonia:a multicenter, open label, randomized factorial clinical trial.

Pharmacokinetic modeling to support WHO-weight band dosing of the new pediatric Darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children

Challenges of recruiting children living with HIV failing antiretroviral therapy into a trial for participants with multi-class drug resistance into a prospective clinical trial

Characteristics of antiretroviral resistance in participants from the SHIELD trial: a pharmacokinetic and safety study evaluating fostemsavir in children and adolescents living with multi-drug resistant HIV